Opinion|Videos|August 1, 2024
Translating Data Updates from FELIX and ZUMA-3 to the Clinical Practice Setting
A medical expert reviews the FELIX study, highlighting its key findings and characteristics while comparing and contrasting it with the ZUMA-3 trial in the context of CAR T-cell therapy for acute lymphoblastic leukemia.
Advertisement
Video content above is prompted by the following:
- Please review the FELIX Study.
- What are pertinent patient characteristics of this trial - What are some key similarities and differences between FELIX and ZUMA-3?
- What noteworthy efficacy or safety outcomes were demonstrated?
- Depth of response, Persistence of CAR-T, and OS
- Safety
- What are the clinical implications of this data?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week.
Check out this September recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
The FDA granted fast track designation to PSV359 for locally advanced unresectable or metastatic FAP-positive solitary fibrous tumors.
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Surgeons at the UC San Francisco have performed over 25,000 robotically assisted minimally invasive surgeries.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
3
VIR-5500 Receives FDA Fast Track Designation in mCRPC
4
The OncFive: Top Oncology Articles for the Week of 10/4/2026
5